KLOW peptide: what’s in the blend and what the research shows

  • By Reed Calder
  • Last reviewed Oct 29, 2026
  • 16 studies and FDA documents checked

In short

KLOW is a pre-mixed vial of four peptides: GHK-Cu, BPC-157, TB-500 and KPV, usually 50, 10, 10 and 10 mg. It’s GLOW with KPV added. No published study has tested the blend. KPV’s research is in cells and mice, and the FDA says it has found no data on KPV in people. None of the four is FDA-approved.

EvidenceCellAnimalHumanNo published study of the blend

KLOW is sold for skin, healing and inflammation at once, which is what you’d expect from four ingredients with four different research stories. This page sorts each claimed benefit by the ingredient it comes from and the evidence behind it.

What’s in a KLOW vial

A typical KLOW vial
Ingredient What it is Typical amount Best human evidence
GHK-Cu A copper-binding peptide found naturally in blood 50 mg Creams and a gel on the skin; no published injection studies
BPC-157 A 15-amino-acid peptide based on a stomach protein 10 mg Three small studies, 30 people, no control group; one more report gave it in a mix
TB-500 A lab-made seven-amino-acid piece of thymosin beta-4 10 mg One report of three patients, TB-500 in a mix; no control group
KPV The last three amino acids of alpha-MSH, a hormone involved in inflammation 10 mg None; the FDA found no human exposure data

Amounts vary by seller; 50, 10, 10 and 10 mg (“KLOW 80”) was the most common split on the listings we reviewed. That makes GHK-Cu about 63% of the vial.

KLOW vs GLOW

GLOW and KLOW side by side
GLOW KLOW
Ingredients GHK-Cu, BPC-157, TB-500 The same three, plus KPV
Typical vial 70 mg: 50 + 10 + 10 80 mg: 50 + 10 + 10 + 10
Studies of the blend None None
In the October 2026 HHS compounding policy BPC-157, TB-500 BPC-157, TB-500, KPV
Not in that policy GHK-Cu GHK-Cu

Our GLOW page covers the three shared ingredients’ skin evidence in more detail.

CAS numbers

A CAS number is a substance’s chemical registry number. Some “research” vials list it in place of a name. A different number usually means a different form, such as a salt, or a different substance. KLOW is a mix, so it has no CAS number of its own; each ingredient has one.

KLOW ingredient CAS numbers
Form CAS number Registry record
GHK-Cu (drug name prezatide copper) 89030-95-5 FDA GSRS
BPC-157 137525-51-0 FDA GSRS
TB-500 (Ac-LKKTETQ, 7 amino acids) 885340-08-9 FDA GSRS
KPV (lysine-proline-valine) 67727-97-3 PubChem

What KPV adds

KPV is three amino acids, lysine, proline and valine, from the end of alpha-MSH, a hormone involved in inflammation and skin color. It is the only difference between KLOW and GLOW.

Its key studies are from 2008. In cells, tiny amounts of KPV calmed inflammatory signaling, and KPV taken by mouth reduced colitis in two mouse models; it enters gut cells through a transporter called PepT1 (Dalmasso et al., 2008). In a second set of mouse colitis studies, KPV-treated mice recovered faster with less inflammation, including mice lacking the receptor alpha-MSH normally acts on (Kannengiesser et al., 2008).

Since then, most KPV research has been about ways to deliver it to an inflamed gut in mice. We haven’t found a human trial, and the FDA says it has not identified any data on people exposed to KPV (FDA, 2026).

EvidenceCellAnimalHumanNo human studies of KPV

KPV’s clearest results came from mice with gut inflammation, given KPV by mouth in one key study. In KLOW it’s injected along with three other peptides, a use no study has tested.

The claimed benefits, checked

KLOW’s claimed benefits and what they rest on
Claim you’ll see Comes from Best evidence we found Tested in
Firmer skin, more collagen GHK-Cu Collagen up in cells; small cream studies; the one randomized skin trial found no measurable difference (Miller et al., 2006) Cells; people (creams only)
Faster tendon and muscle healing BPC-157, TB-500 One rat tendon study: TB-500 helped, BPC-157 didn’t reach significance, both together added nothing (Biçer et al., 2026) Rats
Less inflammation, a calmer gut KPV Reduced colitis in mice (Dalmasso et al., 2008) Cells; mice
Wound healing GHK-Cu, TB-500 GHK-Cu gel on diabetic foot ulcers (Mulder et al., 1994); the TB-500 sequence on mouse wounds (Philp et al., 2003) People (gel on skin); mice
Works better combined All four None. The only test of two ingredients together found no added benefit Not tested

None of these were tested with KLOW itself.

The other three ingredients

No published study has tested KLOW, or GLOW, or all of these peptides together.

The closest thing: two of the ingredients in rats

One study has tested two blend ingredients together. In 32 rats with a repaired Achilles tendon, TB-500 made the tendon stronger and better organized, BPC-157 didn’t reach significance, and giving both added nothing over TB-500 alone (Biçer et al., 2026). It’s one small animal study, but it’s the only direct test of combining them, and more wasn’t better.

EvidenceCellAnimalHuman1 study, 8 rats per group

GHK-Cu: mostly creams on the skin

In cells grown in a dish, GHK-Cu increased the collagen that skin cells made (Maquart et al., 1988). In people, a GHK-Cu gel applied to diabetic foot ulcers closed more of the wound than a plain gel, a median of 98.5% against 60.8%, in a trial run with the gel’s developer (Mulder et al., 1994).

The facial results quoted on many pages, such as firmer skin and fewer fine lines in 12-week studies of 41 to 71 women, come from a review by GHK’s discoverer, whose listed affiliation is a skin-care company. The studies it cites for those results are a 2002 conference presentation, a university report and a book chapter, not peer-reviewed papers (Pickart et al., 2015).

The one randomized GHK-Cu skin trial we found in PubMed tested skin care after laser resurfacing. Blinded measurements found no difference in redness, wrinkles or overall skin quality. Patients using GHK-Cu rated their skin better (Miller et al., 2006; 13 patients).

EvidenceCellAnimalHumanHuman studies used creams and gels, not injections

BPC-157

BPC-157 has a large body of animal research. In people, a 2026 systematic review found three small studies, 30 people in all, none with a control group (Poolton et al., 2026).

EvidenceCellAnimalHuman3 uncontrolled studies

TB-500

No published study has given TB-500 to people, and the FDA’s 2026 review found no toxicity studies (FDA, 2026). Our TB-500 page covers its six cell and animal studies.

EvidenceCellAnimalHumanNo human studies

Side effects and safety

  • No study has measured KLOW’s side effects. The side effects listed on clinic and seller pages, such as stinging where the needle goes in, come from customer reports, not trials.
  • Each ingredient raised FDA concerns. When the FDA reviewed requests to let pharmacies compound these peptides, it listed the concerns below (FDA, 2026).
FDA safety concerns, April 2026
Ingredient What the FDA flagged
GHK-Cu, injected Possible immune reactions from clumping and impurities; limited data in people
BPC-157 Possible immune reactions; impurity concerns; little or no safety information for the proposed routes of use
TB-500 Possible immune reactions from clumping and impurities; important safety information missing
KPV No data on people exposed to it, by any route
  • Copper. Copper is roughly 15% of GHK-Cu’s weight, so the 50 mg in a typical vial carries several milligrams of it. We haven’t found a study of copper levels in people who inject GHK-Cu.
  • One vial, fixed ratio. In a pre-mixed vial, changing the amount of one ingredient changes all four. We haven’t found published data on how stable these peptides are mixed together.
  • What reviewers conclude. A 2026 review for sports medicine doctors found rigorous human safety data for these unapproved peptides scarce, with potential for serious harm (Mendias and Awan, 2026).

Legal and approval status

  • Not FDA-approved. Neither KLOW nor any of its ingredients is approved for any use.
  • GHK-Cu has no compounding route for injection. Requests to let pharmacies compound GHK-Cu were withdrawn in April 2026; in May one was restored for non-injectable use only. The FDA lists GHK-Cu “except for injectable routes” as under evaluation and plans to consult its advisory committee before the end of February 2027 (FDA, 2026).
  • Temporary HHS policy covers BPC-157, TB-500 and KPV, not GHK-Cu. Since October 28, 2026, licensed U.S. pharmacies may compound BPC-157, TB-500 and KPV and three other peptides with a prescription while the FDA decides. GHK-Cu, the largest ingredient in KLOW, isn’t on that list, and the policy isn’t FDA approval (Reuters, 2026).
  • “Research use only” products aren’t approved for use in people.
  • Banned in sport. TB-500 is on the World Anti-Doping Agency’s prohibited list (FDA, 2026).

What to look for if you research it

We don’t name or link sellers. These checks come from the published analyses:

  • Every ingredient and its amount on the label. The blend name alone doesn’t tell you what’s inside, and vial sizes vary.
  • An identity test for each of the four peptides. A certificate of analysis for a blend should confirm each one by mass spectrometry, not give a single purity number for the whole vial.
  • Labels don’t always match contents. Anti-doping scientists found products sold online as TB-500 weren’t consistent with their labels (Delcourt et al., 2023).

Our guide to what to look for explains what each test on a lab report proves and which routes are legal; how to read a peptide study explains how to judge the studies sellers cite.

What’s still unknown

  • Whether KLOW does anything in people.
  • Whether KPV does anything in people, by any route.
  • Whether adding KPV changes anything compared with GLOW. No study compares them.
  • What injected GHK-Cu does, and whether four peptides stay stable mixed in one vial.

Retracted and flagged studies

A retracted study has been pulled by its journal, usually for serious errors or misconduct, and its results shouldn’t be relied on. A withdrawn paper was pulled, often before final publication. An expression of concern means the journal has flagged a problem it is still looking into.

We check every study this page cites against PubMed and the Retraction Watch database, and search both for flagged studies that mention KLOW's ingredients. We recheck every month. Last checked Nov 11, 2026.

Flagged studies that mention KLOW's ingredients

Retracted, withdrawn and flagged studies
Study What it was about Status
Grubisic et al., 2025 Stable Gastric Pentadecapeptide BPC 157 as a Therapy of Severe Electrolyte Disturbances in Rats. Withdrawn · notice
Li et al., 2023 Deficiency of endothelial sirtuin1 in mice stimulates skeletal muscle insulin sensitivity by modifying the secretome. Retracted (2026) · notice
Zhang et al., 2021 Tβ4 ameliorates oxidative damage and apoptosis through ERK/MAPK and 5-HT1A signaling pathway in Aβ insulted SH-SY5Y cells. Withdrawn (2021) · notice
Bokor et al., 2018 Molecular Motions and Interactions in Aqueous Solutions of Thymosin-β4 , Stabilin C-Terminal Domain (CTD) and Their 1:1 Complex Studied by 1 H NMR Spectroscopy. Retracted (2020) · notice
Li et al., 2017 MiR-200a mediates protection of thymosin beta 4 in cardiac microvascular endothelial cells as a novel mechanism under hypoxia-reoxygenation injury. Retracted (2019) · notice
Lee et al., 2013 The role of thymosin beta 4 on odontogenic differentiation in human dental pulp cells. Retracted (2025) · notice
Smart et al., 2002 A differential screen for putative targets of the bHLH transcription factor Hand1 in cardiac morphogenesis. Retracted (2002) · notice

Studies this page relies on

Status of every study cited on this page
Study Published in Status
Maquart et al., 1988 FEBS Lett No retraction or concern
Philp et al., 2003 Wound Repair Regen No retraction or concern
Miller et al., 2006 Arch Facial Plast Surg No retraction or concern
Mulder et al., 1994 Wound Repair Regen No retraction or concern
Dalmasso et al., 2008 Gastroenterology No retraction or concern
Kannengiesser et al., 2008 Inflamm Bowel Dis No retraction or concern
Pickart et al., 2015 Biomed Res Int No retraction or concern
Delcourt et al., 2023 Drug Test Anal No retraction or concern
Mayfield et al., 2026 Am J Sports Med No retraction or concern
Mendias and Awan, 2026 Sports Med No retraction or concern
Biçer et al., 2026 Jt Dis Relat Surg No retraction or concern
Poolton et al., 2026 Acta Orthop Belg No retraction or concern

Bring your questions to other researchers

Our forum opens once 100 researchers join the waitlist. Members post studies, ask what they actually found, and answer with sources.

Questions

What does KLOW peptide do?

Nobody knows, because the blend hasn’t been studied. Each ingredient is sold for a different reason: GHK-Cu for skin, BPC-157 and TB-500 for healing, KPV for inflammation. The table above shows the evidence behind each.

What is KPV?

A three-amino-acid peptide from the end of alpha-MSH. It reduced gut inflammation in mice (Dalmasso et al., 2008). The FDA says it has found no data on KPV in people.

How many days a week do people take KLOW?

There’s no schedule from a study. No study has given KLOW to people, so any schedule you see online is a seller’s or user’s choice, not a study result.

How do you mix a KLOW 80 vial?

We don’t publish mixing or injection instructions. No study has tested the blend, so there’s no dose, schedule or storage time from a study, and we haven’t found stability data for the four peptides mixed together.

Is KLOW better than GLOW?

No study compares them, and neither has been tested. KLOW adds KPV, whose evidence is in mice. See the side-by-side table.

Is KLOW legal?

It isn’t FDA-approved. A temporary HHS policy lets pharmacies compound three of its four ingredients with a prescription, but not GHK-Cu, the largest. Products sold as “research use only” aren’t approved for use in people.

Sources

  1. Dalmasso G, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-78. PubMed 18061177
  2. Kannengiesser K, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(3):324-31. PubMed 18092346
  3. Maquart FX, et al. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Lett. 1988;238(2):343-6. PubMed 3169264
  4. Mulder GD, et al. Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper. Wound Repair Regen. 1994;2(4):259-69. PubMed 17147644
  5. Pickart L, Vasquez-Soltero JM, Margolina A. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int. 2015;2015:648108. PubMed 26236730
  6. Miller TR, et al. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg. 2006;8(4):252-9. PubMed 16847171
  7. Poolton JT, et al. Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review. Acta Orthop Belg. 2026;92(3). PubMed 42885452
  8. Biçer O, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats. Jt Dis Relat Surg. 2026;37(3):822-37. PubMed 42542926
  9. Philp D, et al. Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in diabetic and aged mice. Wound Repair Regen. 2003;11(1):19-24. PubMed 12581423
  10. Mayfield CK, et al. Injectable peptide therapy: a primer for orthopaedic and sports medicine physicians. Am J Sports Med. 2026;54(1):223-9. PubMed 41476424
  11. Mendias CL, Awan TM. Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance. Sports Med. 2026;56(8):1921-35. PubMed 41966639
  12. Delcourt V, et al. TB500/TB1000 and SGF1000: A scientific approach for a better understanding of misbranded and adulterated drugs. Drug Test Anal. 2023;15(4):458-64. PubMed 36482504
  13. U.S. Food and Drug Administration. Safety risks associated with certain bulk drug substances nominated for use in compounding. Content current as of April 22, 2026. FDA page
  14. U.S. Food and Drug Administration. Bulk drug substances nominated for use in compounding under section 503A. Updated May 14, 2026. FDA document
  15. U.S. Food and Drug Administration. Evaluation of TB-500-related bulk drug substances. Pharmacy Compounding Advisory Committee briefing document, July 23-24, 2026. FDA document
  16. Reuters. U.S. health department to allow temporary sale of some unapproved peptides. October 28, 2026. Article
  17. U.S. Food and Drug Administration. Global Substance Registration System: Prezatide copper (UNII 6BJQ43T1I9). GSRS
  18. U.S. Food and Drug Administration. Global Substance Registration System: BPC-157 (UNII 8ED8NXK95P). GSRS
  19. U.S. Food and Drug Administration. Global Substance Registration System: TB-500 (UNII QHK6Z47GTG). GSRS
  20. National Library of Medicine. PubChem compound record: KPV (lysine-proline-valine) (CID 125672). PubChem

Last reviewed Oct 29, 2026. Approval and compounding status change often; we recheck this page when they do. Nothing here is medical advice; see our medical disclaimer. Found a mistake? Email editors@peptideresearchstudy.com.